Nuvox Pharma, LLC
Publicly observedTucson, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Tucson | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Nuvox Pharma, LLC | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | WHNYG96UDLJ8 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant22 Sept 2025Publicly observed
NIH SBIR/STTR award: Liquid Biopsy in Glioblastoma Treated with Chemoradiation and an Oxygen Therapeutic
USD 1,057,531.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant22 Sept 2025Publicly observed
NIH SBIR/STTR award: Liquid Biopsy in Glioblastoma Treated with Chemoradiation and an Oxygen Therapeutic
USD 919,366.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant15 Apr 2023Publicly observed
NIH SBIR/STTR award: Dodecafluoropentane emulsion (DDFPe), NanO2™ as Cerebroprotectant in Ischemic Stroke
USD 299,943.00 · National Institute of Neurological Disorders and Stroke · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.